Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Driving down the cost of drug discovery

David Leahy shares his thoughts on driving down drug discovery costs and how this will, in time, allow for better development of personalised medicine. While the pharma industry may believe drug discovery has been fully optimized, David Leahy disagrees. As the...

Articles

Personalised healthcare and the patient

We interview Dr Bob Holland of AstraZeneca on recent advances in personalised medicine, how these will impact on the patient and AstraZeneca’s personalised healthcare strategy. As personalised medicine slowly becomes a reality it is easy to focus on the therapeutic advances and forget about the impact...

Articles

Interview with Kevin Hrusovsky part 1: molecular interaction...

In the first of this three-part interview series, Kevin Hrusovsky shares the most exciting recent advances in understanding molecular interactions of a disease. Recently we have seen some very exciting breakthrough in our understanding of molecular interactions of diseases, notably in breast cancer...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access